Supernus Receives FDA Tentative Approval for Expanded Label

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Supernus Receives FDA Tentative Approval for Expanded Label of Trokendi XR® to Include Migraine Prophylaxis in Adults

ROCKVILLE, Md., Aug. 19, 2016 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, today announced that the Food and Drug Administration (FDA) has granted tentative approval to the Company’s Supplemental New Drug Application (sNDA) requesting a label expansion for Trokendi XR to include prophylaxis of migraine headache in adults.

The approval of the sNDA is tentative because the FDA has determined that the drug meets all of the required quality, safety, and efficacy standards for approval, but is subject to the pediatric exclusivity which expires March 28, 2017. Final approval may not be made effective until this exclusivity period has expired.  

In addition, the Company announced today that the FDA has granted final approval to expand the label for Trokendi XR for monotherapy treatment of partial onset seizures to include adults and pediatric patients 6 years and older, rather than 10 years and older.

“We will continue to work with the FDA to gain final approval upon the expiration of pediatric exclusivity,” stated Jack Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals. “We are prepared and ready to launch the migraine indication upon receiving full FDA approval.”

About Trokendi XR

Trokendi XR is the first approved novel once-daily extended release formulation of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalized tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.

For current full prescribing and safety information, click here

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of Impulsive Aggression in ADHD patients and SPN-812 for the treatment of ADHD.

Forward-Looking Statements:

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information, but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company's ability to sustain and increase its profitability; the Company's ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company's corporate strategy; the Company's future financial performance and projected expenditures; the Company's ability to increase the number of prescriptions written for each of its products; the Company's ability to increase its net revenue; the Company's ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company's product research and development activities, including the timing and progress of the Company's clinical trials, and projected expenditures; the Company's ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company's product candidates; the Company's ability to protect its intellectual property and operate its business without infringing upon the intellectual property rights of others; the Company's expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company's product candidates; the accuracy of the Company's estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company's ability to increase its manufacturing capabilities for its products and product candidates; the Company's projected markets and growth in markets; the Company's product formulations and patient needs and potential funding sources; the Company's staffing needs; and other risk factors set forth from time to time in the Company's SEC filings made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.

CONTACT: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 Or Investor Contact: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

NVE Revenue Pull-Forward Raises Hard Investor Questions

Updated Category News Views 110

A Quarter Can Look Great Until It Doesn’t NVE investors got a nasty lesson in revenue timing, the sort that makes even old hands check the fine print twice. On July 22, 2026, the company reported sequential revenue growth of 43% and net-income growth of 23%. The next trading day, shares vaulted $47.53, or 54%. Then came October, and the floor gave way: NVE reported that...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
Yiwu Squishies Turn Viral Demand Into Factory Backlogs Worldwide

Updated Category News Views 87

A pizza-shaped stress toy booking more than one million units is the sort of detail that makes a jaded market watcher sit up before rolling his eyes at the word “viral.” Yiwu’s squishy-toy surge appears to have moved beyond a few social-media impulses and into actual factory scheduling, repeat purchase orders and supermarket procurement. That is meaningful. It is...

Continue Reading
Five Films Put Modern Infrastructure Under a Lens

Updated Category News Views 121

Most infrastructure only earns a thought when it breaks, and that is precisely the nerve these films are trying to touch. Nicely Done Productions has released the final five installments of its ten-part Threads of Connectivity documentary series, hosted on National Geographic's global digital platform. The subjects are illycaffè, Cargill, Honeywell Aerospace, Western...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
MFB Bancorp Offering Puts Chicago Bank Conversion First

Updated Category News Views 70

A small Chicago thrift is asking investors to fund a corporate makeover, and the fine print matters more than the $10 sticker price. MFB Bancorp has commenced an offering tied to the planned conversion of Mutual Federal Bancorp, MHC from a mutual holding company structure into a stock holding company. This is not some high-growth bank story with a shiny new branch map. It...

Continue Reading
StoneX Selloff Puts Earnings Quality Under a Harsh Lens

Updated Category News Views 111

A revenue beat can turn downright useless when the profit line springs a leak. StoneX Group delivered operating revenue above expectations and record full-year results, then watched investors hammer the stock after fiscal fourth-quarter diluted earnings per share landed at $0.66. That was $0.15 below the roughly $0.81 consensus cited in the notice, and other estimates...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 108

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Growth of the Global Gifts Retailing Market

Updated Category News Views 120

The Gifts Retailing Market is Evolving Rapidly The global gifts retailing industry is projected to experience substantial growth, with estimates indicating an increase of USD 11.01 billion from 2024 to 2028. Several influential factors are driving this trend, notably the rising demand for seasonal decorations and a stronger gifting culture. As consumers increasingly...

Continue Reading
Exploring the Risks Behind the Monumental Rise of Big Tech

Updated Category News Views 163

Understanding the Current Landscape of Big Tech Investment In recent discussions about the tech industry, significant concerns have bubbled to the surface regarding the sustainability of current market valuations. Analysts have pointed out that the optimism surrounding the surge in equity prices may be fueled by unrealistic expectations. John Hussman notably remarked on...

Continue Reading
Senator Markwayne Mullin Makes Notable Stock Purchase in LPL

Updated Category News Views 246

Senator Markwayne Mullin's Recent Stock Transactions Recent financial disclosures reveal that Senator Markwayne Mullin has made a significant investment in LPL Financial Holdings Inc (NASDAQ: LPLA). The purchase, valued between $233,016 and $670,000, was filed recently and adds to his active trading portfolio. This transaction indicates Mullin's ongoing interest in the...

Continue Reading
Pathward Financial: Sale of Insurance Business Extended

Updated Category News Views 123

Pathward Financial, Inc. (NASDAQ: CASH), known as Meta Financial Group in the past, extended the closing of its commercial insurance premium finance business sale to October 22, from an initial deadline of October 1. Traders were quick to sniff out that this delay wasn’t just a minor hiccup—it pointed to deeper operational challenges. Delays and What They Mean for...

Continue Reading
Vallourec's Major Supply Order from ADNOC Signals Growth

Updated Category News Views 198

Vallourec's Major Supply Agreement with ADNOC Vallourec, a global leader in premium seamless tubular solutions, has successfully secured a significant order from the Abu Dhabi National Oil Company (ADNOC). This order includes supplying over 30,000 tons of carbon steel tubulars and related accessories, prominently featuring VAM premium connections. This transaction forms...

Continue Reading